TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with chemotherapy related anemia~* Patients with a diagnosis of malignancy~* Patients with initial weekly PROCRIT (Epoetin alfa) therapy for at least 4 weeks~* Patients must have received PROCRIT (Epoetin alfa) maintenance therapy with less frequent dosing (e.g. every 2 weeks, every 3 weeks, every 4 weeks) for at least 6 weeks immediately following once weekly dosing.~Exclusion Criteria:~* No previous diagnosis of hemolytic anemia or myelodysplasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>= 18 years old~* Source of infection~* Two or more of systemic inflammatory response syndrome criteria~* Systolic blood pressure \< 90 mmHg after a fluid bolus OR lactate \>= 4 mmol/L~* A central line has been placed for CVP/ScvO2 monitoring~Exclusion Criteria:~* Pregnancy~* Acute stroke~* Acute cardiogenic pulmonary edema~* Status asthmaticus~* Unstable cardiac dysrhythmia~* Active hemorrhage~* Acute seizure~* Drug overdose~* Trauma~* Requiring immediate surgery~* Do-not-resuscitate status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MiCHO (Type: EXPERIMENTAL): A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
- EGDT (Type: ACTIVE_COMPARATOR): A 6-hour resuscitation protocol utilizing CVP/ScvO2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.~2. At least 18 years of age.~3. Advanced stage epithelial ovarian cancer: FIGO stage IIIb, IIIc or IV. (For FIGO staging classification, please refer to Appendix 7).~4. A biopsy or cytology confirming the presence of high-grade serous epithelial ovarian carcinoma~5. Preoperative imaging (CT and/or MRI), describing metastatic implants, as standard of care.~Exclusion Criteria:~1. Participant has a history of following diseases:~   1. Hyperthyroidism~  2. Autonomously functioning thyroid adenoma~2. Participant has an allergy or hypersensitivity for one or more of the following components:~   1. Iodine (including potassium iodine)~  2. Indocyanine green~3. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.~4. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.~5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device during the surgery itself.~6. Participant has a severe renal impairment (classified as renal function\<30 ml/min/1,73m2 according to CKD-EPI).~7. Participant utilises sodium bisulfite-containing heparin preparations during the day before surgery. For Belgian registered drugs, this contains:~   1. Danaparoid (Orgaran®)~  2. Other low-molecular weight heparins registered in Belgium do not contain sodium bisulfite and are not an exclusion criterion.~8. Participants requires thyroid scintigraphy utilising radioactive iodine one week after surgery.~9. A previous history of major intra-abdominal surgery with potentially major adhesions and/or distorted anatomy.~10. Participants utilises one of the interacting drugs listed in the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primary Debulking Surgery (Type: EXPERIMENTAL): None
- Interval Debulking Surgery (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of colorectal cancer (any stage)~* Any type of prior therapy~* Age \>= 18-39 years for AYA/young adult sample, age 40+ for older comparison group~* For patients on active therapy: must have been diagnosed within the past three months. For survivors: must have completed curative therapy and are 6-24 months post-diagnosis~* Speak English or Spanish~* Ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* Patients who are more than 3 months from diagnosis, and survivors who are more than 24 months from initial diagnosis~* Patients who have a life expectancy of less than 6 months per their medical oncologist~* Patients who are deemed too ill or unable to participate by their medical oncologist (e.g., have cognitive impairment or brain metastases)~* Patients who do not speak English or Spanish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Physical function testing, questionnaire (Type: EXPERIMENTAL): Patients on active treatment complete questionnaires and undergo collection of blood samples and physical function assessments at baseline, and at 3 and 6 months. Survivors in surveillance complete questionnaires and undergo collection of blood sample and physical function assessment at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suitable for and have chosen AS as management for localised prostate cancer~* MRI visible detected lesion ≥0.5 cm in the axial plane, corresponding to the biopsy confirmed region of prostate cancer~* No contraindication to MR scanning~* Aged 18-80 years~* BMI between 19.5 and 35 kg/m2~* Smokers and non-smokers~Exclusion Criteria:~* 5α-reductase inhibitors or testosterone replacement medicines~* warfarin~* surgically implanted pelvic metalwork~* pacemakers or other implanted electronic devices not compatible with MRI~* contra-indications to gadolinium-based contrast agents (including patients with abnormal renal function)~* Glomerular Filtration Rate (GFR) \<60 ml/min~* claustrophobia~* allergies to any of the ingredients of the broccoli soups~* dietary supplements or herbal remedies which may affect the study outcome - unless the volunteer is willing to discontinue taking them for 1 month prior to starting study~* parallel participation in another research project that involves dietary intervention

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- standard broccoli soup (Type: ACTIVE_COMPARATOR): one portion (300 g each) per week of a soup containing standard broccoli
- beneforte extra broccoli soup (Type: EXPERIMENTAL): one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically (histologically or cytologically) proven diagnosis of NSCLC~* Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expected treatment scenarios include:~  * Definitive treatment of stage III disease (most common)~ * Definitive treatment for locoregional recurrence of early stage disease~ * Definitive treatment of unresectable stage II disease~ * Preoperative treatment of stage III disease~ * Postoperative treatment after incomplete resection (uncommon)~ * Radical treatment for a patient with advanced/metastatic disease with the goal of achieving long-term thoracic disease control (e.g., oligometastatic disease where metastases are addressed with resection or stereotactic radiotherapy)~* ECOG Performance Status 0-3 within 30 days prior to registration~* Age ≥ 18~* Ambulates independently or with a cane (use of a walker not permitted)~* Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial. Patients must agree to wear the device provided by the study.~* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.~Exclusion Criteria:~* Patients with a history of another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy for NSCLC~* Patients receiving concurrent treatment for another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy~* Patients receiving thoracic radiotherapy without concurrent chemotherapy are ineligible. Patients receiving concurrent chemotherapy and another form of systemic therapy (e.g., immunotherapy) are eligible. Patients receiving radiotherapy with concurrent immunotherapy or targeted therapy but without chemotherapy are ineligible

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: Usual Care (Type: NO_INTERVENTION): Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.
- Arm II: Usual Care + Continuous physical activity monitoring via a wearable device (Type: EXPERIMENTAL): Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is skeletally mature and between 18 and 70 years of age.~2. DDD and up to Grade I spondylolisthesis or retrolisthesis, requiring decompression and arthrodesis at one or two contiguous levels between L2 and S1.~3. No previous surgery at the same or adjacent level (other than microdiscectomy / laminectomy) at the same or adjacent level.~4. Non-responsive to conservative (non-surgical) treatment for back pain for a minimum of 6 months.~5. Subject understands the conditions of enrollment and is willing to sign and date the Informed Consent.~6. Subject agrees to comply with visit schedule and completing study questionnaires.~Exclusion Criteria:~1. Significant instability of the spine.~2. Requires TLIF at more than 2 levels between L2 and S1.~3. Previously undergone lumbar spine surgery (other than microdiscectomy / laminectomy) at the same or adjacent level.~4. Younger than 18 years of age, or older than 70 years of age.~5. BMI of 40 or greater.~6. History of metabolic bone disease~7. Osteoporosis~8. Diabetes mellitus requiring daily insulin management.~9. Subject has any of the following:~   1. Progressive neuromuscular disease; OR~  2. Autoimmune disease; OR~  3. Active malignancy within the last 15 years; OR~  4. Active hepatitis; OR~  5. AIDS, ARC, or is HIV positive; OR~  6. Syringomyelia at any spinal level; OR~  7. Any other condition that would interfere with the subject self -assessment of pain, function or quality of life.~10. Allergy to implant materials (titanium, titanium alloy).~11. Active systemic infection or infection localized to the site of implantation.~12. Primary or metastatic tumors involving the spine.~13. Open wounds or inadequate issue tissue coverage over the operative site.~14. History of significant mental illness or mental incapacity.~15. Pregnancy or intent to become pregnant.~16. Participating in another investigational study for a similar purpose.~17. Belongs to a vulnerable population that would compromise ability to provide informed consent or compliance with follow-up requirements.~18. Smokers unwilling to cease up to 3 months post-op or recent history of alcohol or other substance abuse within the past 2 years.~19. Workers compensation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- AccuLIF (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Exercise on Depressive Symptoms in Unmedicated Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 - 60 years~2. Major depression according to DSM-IV~3. Living within 30 km of training facilities~4. Able to read and understand informed consent~Exclusion Criteria:~1. Recreational or current drug abuse~2. Having used antidepressant medication within the last 2 months~3. Contraindications to physical exercise~4. Recreational exercise\> 1 hour per week~5. Medication for diabetes, hypertension, or any kidney disease~6. Suicidal behaviour (ham-d17 item3 \> 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
- 2 (Type: PLACEBO_COMPARATOR): Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven CD20+ diffuse large B cell lymphoma (WHO Classification)~* Baseline PET scan available with at least one hypermetabolic lesion~* Aged ≥ 18 years and ≤ 60 years~* Eligible for autologous stem cell transplant~* Patient not previously treated~* Age adjusted International Prognostic Index (aa-IPI) equal to 1, 2 or 3~* Life expectancy ≥ 3 months~* Negative HIV, HBV (anti-HBc negativity) and HCV serologies before inclusion~* Having signed a written informed consent~* Having ability and willingness to comply with study protocol procedures~* Men must agree to use a barrier method of contraception during the treatment period and until 3 months after the last dose of GA101 or rituximab, or ACVBP14 or CHOP14 chemotherapy, whichever is longer~* Women of childbearing potential must agree to use an adequate method of contraception, such as oral contraceptives, intrauterine device, or barrier method of contraception during the treatment period and until 12 months after the last dose of GA101, Rituximab, ACVBP14, or CHOP14 chemotherapy, whichever is longer~Exclusion Criteria:~* Any other histological type of lymphoma~* Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included~* Central nervous system or meningeal involvement by lymphoma~* Contra-indication to any drug contained in the chemotherapy regimens~* Poor cardiac function (LVEF \< 50%) on echocardiogram or MUGA scan~* Poor renal function (creatinine level \> 150\*mol/l or clearance \< 30ml/min), poor hepatic function (total bilirubin level \> 30µmol/l, transaminases \> 2.5 X maximum normal level) unless these abnormalities are related to the lymphoma~* Poor bone marrow reserve as defined by neutrophils \< 1.5 G/L or platelets \< 100 G/L, unless related to bone marrow infiltration~* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma~* Any serious active disease (according to the investigator's decision)~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy~* Pregnant or lactating women~* Adult patient under tutelage~* Prior history of Progressive Multifocal Leukoencephalopathy (PML)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- GA101 (Type: EXPERIMENTAL): GA101 - Chemotherapy (ACVBP or CHOP)
- Rituximab (Type: ACTIVE_COMPARATOR): Rituximab - Chemotherapy (ACVBP or CHOP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must meet all of the following clinical criteria for MCI due to AD or mild AD and must have:~* A Clinical Dementia Rating (CDR)-Global Score of 0.5.~* Objective evidence of cognitive impairment at screening~* An MMSE score between 24 and 30 (inclusive)~* Must have a positive amyloid Positron Emission Tomography (PET) scan~* Must consent to apolipoprotein E (ApoE) genotyping~* If using drugs to treat symptoms related to AD, doses must be stable for at least 8 weeks prior to screening visit 1~* Must have a reliable informant or caregiver~Key Exclusion Criteria:~* Any medical or neurological condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment~* Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of consciousness in the past 1 year~* Clinically significant unstable psychiatric illness in past 6 months~* History of unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within 1 year prior to Screening~* Indication of impaired renal or liver function~* Have human immunodeficiency virus (HIV) infection~* Have a significant systematic illness or infection in past 30 days~* Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities~* Any contraindications to brain magnetic resonance imaging (MRI) or PET scans~* Alcohol or substance abuse in past 1 year~* Taking blood thinners (except for aspirin at a prophylactic dose or less)~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Monthly intravenous (IV) infusion
- High Dose (Type: EXPERIMENTAL): Monthly intravenous (IV) infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is deemed suitable for treatment with radioiodine or antithyroid drugs~* Patient has a thyreotropin (TSH) value below 0,1 mIU/L, measured less than 2 weeks before inclusion~* Patient has a CHADS-VASc-score of 1 point or higher (excluding if 1 point is for female sex only)~* Patient gives written consent to participate in study~Exclusion Criteria:~* Patient has a previously known diagnosis of atrial fibrillation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperthyroid patients (Type: None): Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy